SBC Medical Group Holdings (SBC)
NASDAQ:SBC
Want to see SBC full AI Analyst Report?
Top Page
SBC Medical Group Holdings
(NASDAQ:SBC)
Select Model
Select Model
Rating:66Neutral
Price Target:
$3.50
▼(-21.70% Downside)
Action:Reiterated
Date:05/14/26
The score is supported primarily by strong financial quality (high profitability/ROE and low leverage) and a low P/E valuation, but is held back by weak technicals (price below key moving averages with negative MACD) and near-term fundamental pressure highlighted by contracting revenue and weaker Q1 2026 earnings.
Positive Factors
High Profitability & Margins
Sustained high gross and net margins point to strong pricing power and efficient service delivery in aesthetic clinics. This margin profile supports durable profitability, funds reinvestment in multi-brand expansion and tech, and cushions the business through cyclic revenue swings.
Negative Factors
Structural Franchise Fee Reform
A permanent change to the franchise fee model implemented in April 2025 has structurally lowered reported revenue and altered franchisee economics. This reduces top-line comparability, may depress near-term system revenue, and raises execution risk as the company shifts to new fee dynamics.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability & Margins
Sustained high gross and net margins point to strong pricing power and efficient service delivery in aesthetic clinics. This margin profile supports durable profitability, funds reinvestment in multi-brand expansion and tech, and cushions the business through cyclic revenue swings.
Read all positive factors
SBC Medical Group Holdings (SBC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$295.17M
Dividend YieldN/A
Average Volume (3M)65.67K
Price to Earnings (P/E)9.5
Beta (1Y)0.63
Revenue Growth16.92%
EPS Growth63.88%
CountryUS
Employees863
SectorIndustrials
Sector Strength72
IndustryConsulting Services
Share Statistics
EPS (TTM)0.39
Shares Outstanding102,846,950
10 Day Avg. Volume48,167
30 Day Avg. Volume65,672
Financial Highlights & Ratios
PEG Ratio2.09
Price to Book (P/B)1.79
Price to Sales (P/S)2.56
P/FCF Ratio12.15
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.55
Enterprise Value/Ebitda2.59
Forecast
1Y Price Target
$8.50Price Target Upside90.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.46
Revenue Forecast (FY)$181.01M
SBC Medical Group Holdings Business Overview & Revenue Model
Company Description
SBC Medical Group Holdings Incorporated provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and internationally. The company offers advertising and marketing services; staff management services, such as...
How the Company Makes Money
SBC primarily makes money through fees and revenues tied to the delivery of aesthetic/elective medical services and the management/support of affiliated clinics. Key revenue streams generally include (1) patient-service revenue generated when trea...
SBC Medical Group Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 169.34M | 173.61M | 205.42M | 193.54M | 174.16M |
| Gross Profit | 118.88M | 127.28M | 156.05M | 137.30M | 114.83M |
| EBITDA | 71.18M | 84.91M | 77.28M | 85.87M | 29.64M |
| Net Income | 40.79M | 50.99M | 46.61M | 39.37M | 6.32M |
Balance Sheet | |||||
| Total Assets | 388.02M | 380.45M | 266.08M | 258.81M | 225.48M |
| Cash, Cash Equivalents and Short-Term Investments | 167.31M | 164.09M | 125.04M | 103.02M | 53.64M |
| Total Debt | 20.45M | 51.64M | 12.21M | 22.87M | 16.13M |
| Total Liabilities | 117.64M | 117.14M | 71.06M | 115.00M | 117.63M |
| Stockholders Equity | 255.34M | 248.28M | 195.11M | 142.16M | 105.25M |
Cash Flow | |||||
| Free Cash Flow | 44.06M | 36.55M | 17.17M | 39.44M | -24.99M |
| Operating Cash Flow | 46.22M | 38.92M | 20.58M | 50.64M | -47.37K |
| Investing Cash Flow | -20.52M | -20.97M | -10.10M | 1.82M | -32.65M |
| Financing Cash Flow | 22.48M | 24.04M | 22.97M | 6.14M | -7.98M |
SBC Medical Group Holdings Technical Analysis
Negative
4.47
Price Trends
3.69
Negative
4.01
Negative
4.00
Negative
Market Momentum
-0.24
Positive
27.06
Positive
9.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBC, the sentiment is Negative. The current price of 4.47 is above the 20-day moving average (MA) of 3.22, above the 50-day MA of 3.69, and above the 200-day MA of 4.00, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 27.06 is Positive, neither overbought nor oversold. The STOCH value of 9.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBC.
SBC Medical Group Holdings Risk Analysis
SBC Medical Group Holdings disclosed 78 risk factors in its most recent earnings report. SBC Medical Group Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SBC Medical Group Holdings Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $295.17M | 9.48 | 16.38% | ― | 16.92% | 63.88% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | $232.89M | -18.76 | -4.11% | ― | -8.43% | -115.12% | |
60 Neutral | $936.56M | 24.15 | 23.64% | 0.97% | 10.50% | -3.09% | |
51 Neutral | $147.62M | -3.31 | -49.24% | 6.74% | -13.38% | 9.50% | |
50 Neutral | $129.09M | -1.24 | -39.22% | ― | -7.06% | 38.03% | |
45 Neutral | $37.02M | 5.84 | 82.49% | ― | -2.33% | -104.25% |
* Industrials Sector Average
SBC
SBC Medical Group Holdings
2.89
-0.58
-16.71%
CRAI
Cra International
144.99
-40.25
-21.73%
FORR
Forrester Research
6.75
-3.86
-36.38%
FC
Franklin Covey Company
21.40
-1.53
-6.67%
RGP
Resources Connection
4.29
-0.42
-8.84%
AERT
Aeries Technology
0.73
0.06
9.09%
SBC Medical Group Holdings Corporate Events
Business Operations and StrategyFinancial Disclosures
SBC Medical Reports Weaker Q1 2026 Results, Outlines Growth
Negative
May 14, 2026
On May 14, 2026, SBC Medical Group Holdings reported first-quarter 2026 results showing $43 million in revenue, down 9% year over year, and net income of $11 million, a 47% decline with margin compressed to 26%. EBITDA fell 26% to $18 million with...
Business Operations and StrategyPrivate Placements and Financing
SBC Medical Group Announces CEO Secondary Share Offering
Neutral
Apr 23, 2026
On April 19, 2026, SBC Medical Group Holdings Incorporated entered into an underwriting agreement with Maxim Group LLC for a secondary offering of 3,100,000 shares of its common stock held by CEO and chairman Dr. Yoshiyuki Aikawa, with underwriter...
Business Operations and StrategyFinancial Disclosures
SBC Medical Group Outlines 2026 Growth Strategy Amid Transition
Positive
Mar 27, 2026
On March 27, 2026, SBC Medical Group Holdings reported fourth-quarter and full-year 2025 results showing a business in transition, with revenue contracting but profitability improving as earlier restructuring and franchise fee changes worked throu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.